Apolipoprotein E and progression of chronic kidney disease

JAMA

Volumn 293, Issue 23, 2005, Pages 2892-2899

  Hsu, Charles C ^a   Kao, W H Linda ^a   Coresh, Josef ^a   Pankow, James S ^b   Marsh Manzi, Jane ^a   Boerwinkle, Eric ^c   Bray, Molly S ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUSE OF DEATH; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; EUROPEAN AMERICAN; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STATISTICAL MODEL; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; CAUCASIAN; CHRONIC DISEASE; GENETICS; KIDNEY DISEASE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEGRO; PATHOPHYSIOLOGY;

AFRICAN CONTINENTAL ANCESTRY GROUP; APOLIPOPROTEINS E; CHRONIC DISEASE; DIABETES MELLITUS; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 20444491653     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.293.23.2892     Document Type: Article

References (41)

1. Krop JS, Coresh J, Chambless LE, et al. A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs whites with diabetes: the Atherosclerosis Risk in Communities study. Arch Intern Med. 1999;159:1777-1783.
2. Freedman BI, Satko SG. Genes and renal disease. Curr Opin Nephrol Hypertens. 2000;9:273-277.
3. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260-269.
4. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities study. Kidney Int. 2000;58:293-301.
5. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-537.
6. Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279:751-755.
7. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
8. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. JAMA. 1994;272:1666-1671.
9. Liberopoulos E, Siamopoulos K, Elisaf M. Apolipoprotein E and renal disease. Am J Kidney Dis. 2004;43:223-233.
10. Zeleny M, Swertfeger DK, Weisgraber KH, Hui DY. Distinct apolipoprotein E isoform preference for inhibition of smooth muscle cell migration and proliferation. Biochemistry. 2002;41:11820-11823.
11. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A protective role for kidney apolipoprotein E: regulation of mesangial cell proliferation and matrix expansion. J Biol Chem. 2001;276:49142-49147.
12. Boizel R, Benhamou PY, Corticelli P, et al. ApoE polymorphism and albuminuria in diabetes mellitus: a role for LDL in the development of nephropathy in NIDDM? Nephrol Dial Transplant. 1998;13:72-75.
13. Araki S, Moczulski DK, Hanna L, Scott LJ, Warram JH, Krolewski AS. APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes. 2000;49:2190-2195.
14. Werle E, Fiehn W, Hasslacher C. Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients. Diabetes Care. 1998;21: 994-998.
15. Araki S, Koya D, Makiishi T, et al. APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a prospective observational follow-up study. Diabetes Care. 2003;26:2416-2420.
16. Eto M, Horita K, Morikawa A, et al. Increased frequency of apolipoprotein epsilon 2 allele in noninsulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet. 1995;48:288-292.
17. Eto M, Saito M, Okada M, et al. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis. 2002;40:243-251.
18. Hsieh MC, Lin SR, Yang YC, Chen HC, Lin JN, Shin SJ. Higher frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan. J Nephrol. 2002;15:368-373.
19. Ha SK, Park HS, Kim KW, et al. Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant. 1999;14:2144-2149.
20. Liberopoulos EN, Miltiadous GA, Cariolou M, Kalaitzidis R, Siamopoulos KC, Elisaf MS. Influence of apolipoprotein E polymorphisms on serum creatinine levels and predicted glomerular filtration rate in healthy subjects. Nephrol Dial Transplant. 2004;19:2006-2012.
21. Kimura H, Suzuki Y, Gejyo F, et al. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis. 1998;31:666-673.
22. Oda H, Yorioka N, Ueda C, Kushihata S, Yamakido M. Apolipoprotein E polymorphism and renal disease. Kidney Int Suppl. 1999;71:S25-S27.
23. Liberopoulos EN, Miltiadous GA, Cariolou M, Tselepis AD, Siamopoulos KC, Elisaf MS. The influence of serum apolipoprotein E concentration and polymorphism on serum lipid parameters in hemodialysis patients. Am J Kidney Dis. 2004;44:300-308.
24. Schmidt S, Klaver C, Saunders A, et al. A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy. Ophthalmic Genet. 2002;23:209-223.
25. National Heart, Lung, and Blood Institute. ARIC Manual of Operations. Chapel Hill: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
26. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38:1933-1953.
27. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1-266.
28. Morrison AC, Ballantyne CM, Bray M, Chambless LE, Sharrett AR, Boerwinkle E. LPL polymorphism predicts stroke risk in men. Genet Epidemiol. 2002;22:233-242.
29. Eckfeldt JH, Chambless LE, Shen YL. Short-term, within-person variability in clinical chemistry test results: experience from the Atherosclerosis Risk in Communities Study. Arch Pathol Lab Med. 1994;118:496-500.
30. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med. 1996;2:405-411.
31. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet. 2003;361:567-571.
32. Hadjadj S, Gallois Y, Simard G, et al. Lack of relationship in long-term type 1 diabetic patients between diabetic nephropathy and polymorphisms in apolipoprotein epsilon, lipoprotein lipase and cholesteryl ester transfer protein. Nephrol Dial Transplant. 2000;15:1971-1976.
33. Onuma T, Laffel LM, Angelico MC, Krolewski AS. Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol. 1996;7:1075-1078.
34. Shcherbak NS. Apolipoprotein E gene polymorphism is not a strong risk factor for diabetic nephropathy and retinopathy in type I diabetes: case-control study. BMC Med Genet. 2001;2:8.
35. Tarnow L, Stehouwer CD, Emeis JJ, et al. Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. Nephrol Dial Transplant. 2000;15:625-630.
36. Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 2003;60:185-189.
37. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl. 1991;31:S29-S34.
38. Nishida Y, Yorioka N, Oda H, Yamakido M. Effect of lipoproteins on cultured human mesangial cells. Am J Kidney Dis. 1997;29:919-930.
39. Sanan DA, Weisgraber KH, Russell SJ, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994;94:860-869.
40. Yorioka N, Nishida Y, Oda H, Watanabe T, Yamakido M. Apolipoprotein E polymorphism in IgA nephropathy. Nephron. 1999;83:246-249.
41. Ji ZS, Pitas RE, Mahley RW. Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans: apolipoproteins E3 and E2 greater than E4. J Biol Chem. 1998;273:13452-13460.